Clinical Trials Browser

Has results × cabozantinib × 90 days × Clear all

NCT02243605 2026-04-13

Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

Phase 2 Active not recruiting

90 enrolled 15 charts

Sarcoma, Ewing, Osteosarcoma

NCT02867592 2026-04-13

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Phase 2 Active not recruiting

109 enrolled 24 charts

CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT03375320 2026-04-13

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Phase 3 Active not recruiting

298 enrolled 14 charts 3 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03914300 2026-04-13

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Phase 2 Active not recruiting

11 enrolled 11 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT04079712 2026-04-13

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Phase 2 Active not recruiting

17 enrolled 12 charts

EndocrineNETThoracic

Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04211337 2026-03-19

LIBRETTO-531

Phase 3 Active not recruiting

291 enrolled 16 charts 3 FDA

Carcinoma, Medullary

NCT04338269 2026-03-19

CONTACT-03

Phase 3 Terminated

522 enrolled 22 charts

Carcinoma, Renal Cell

NCT03945773 2026-03-13

CaboPoint

Phase 2 Completed

127 enrolled 17 charts

Carcinoma, Renal Cell

NCT04091750 2026-03-03

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Phase 2 Active not recruiting

14 enrolled 9 charts

Melanoma

NCT01068782 2026-02-25

Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Phase 2 Terminated

19 enrolled 10 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT03468218 2026-01-23

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Phase 2 Active not recruiting

36 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck